Tumor lysis syndrome.
Vachani
Carolyn
C
OncoLink at Abramson Cancer Center, University of Pennsylvania, USA.
D000368:Aged; D000493:Allopurinol / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000009:adverse effects; D003681:Dehydration / Q000150:complications; D004317:Doxorubicin / Q000009:adverse effects; D016903:Drug Monitoring; D004630:Emergencies / Q000451:nursing; D005260:Female; D005440:Fluid Therapy; D006074:Gout Suppressants / Q000627:therapeutic use; D006801:Humans; D016393:Lymphoma, B-Cell / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D009730:Nursing Assessment; D009859:Oncology Nursing / Q000379:methods*; D011241:Prednisone / Q000009:adverse effects; D012307:Risk Factors; D015275:Tumor Lysis Syndrome / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D014503:Urate Oxidase / Q000627:therapeutic use; D014750:Vincristine / Q000009:adverse effects
D006074:Gout Suppressants; C469709:rasburicase; D014750:Vincristine; D000493:Allopurinol; D004317:Doxorubicin; D003520:Cyclophosphamide; D014503:Urate Oxidase; D011241:Prednisone